Capital Impact Advisors LLC Purchases 26,751 Shares of Exelixis, Inc. $EXEL

Capital Impact Advisors LLC boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 15.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 202,305 shares of the biotechnology company’s stock after buying an additional 26,751 shares during the quarter. Exelixis makes up approximately 1.9% of Capital Impact Advisors LLC’s portfolio, making the stock its 25th biggest position. Capital Impact Advisors LLC’s holdings in Exelixis were worth $8,355,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Assetmark Inc. raised its stake in shares of Exelixis by 1,230.8% during the third quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company’s stock worth $131,994,000 after acquiring an additional 2,955,813 shares in the last quarter. Norges Bank purchased a new stake in shares of Exelixis in the 2nd quarter valued at $122,099,000. Qube Research & Technologies Ltd boosted its stake in shares of Exelixis by 120.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock valued at $134,306,000 after purchasing an additional 1,665,110 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Exelixis by 42.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock valued at $231,951,000 after purchasing an additional 1,580,567 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Exelixis by 20.7% during the 3rd quarter. AQR Capital Management LLC now owns 9,181,359 shares of the biotechnology company’s stock valued at $379,190,000 after purchasing an additional 1,575,280 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Bank of America downgraded shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price target for the company. in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research note on Thursday, January 22nd. Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 5th. Royal Bank Of Canada lowered their target price on Exelixis from $46.00 to $43.00 and set a “sector perform” rating for the company in a research note on Monday, March 2nd. Finally, Barclays increased their target price on Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. Ten investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $46.94.

Insider Activity at Exelixis

In other news, EVP Patrick J. Haley sold 67,814 shares of Exelixis stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total value of $2,951,265.28. Following the sale, the executive vice president directly owned 381,908 shares in the company, valued at approximately $16,620,636.16. This trade represents a 15.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack L. Wyszomierski sold 99,574 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total value of $4,382,251.74. Following the transaction, the director directly owned 279,942 shares in the company, valued at $12,320,247.42. This trade represents a 26.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 362,849 shares of company stock worth $15,917,463 over the last 90 days. 2.82% of the stock is owned by insiders.

Exelixis Stock Up 0.2%

Shares of Exelixis stock opened at $41.24 on Friday. The company’s fifty day simple moving average is $43.31 and its two-hundred day simple moving average is $41.69. Exelixis, Inc. has a 12-month low of $32.38 and a 12-month high of $49.62. The firm has a market cap of $10.71 billion, a PE ratio of 14.89, a price-to-earnings-growth ratio of 0.93 and a beta of 0.41.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.74 by $0.20. The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.55 earnings per share. As a group, sell-side analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.